 |
27 Products |  |
63 Diseases | | 27 Products |
|
80 Trials |  |
3278 News |  |
| «12...37383940414243444546474849 |
- | LEO 35299 / LEO Pharma
New P1 trial: A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris (clinicaltrials.gov) - Apr 17, 2012
P1, N=24, Completed, Sponsor: LEO Pharma
- | Innohep (tinzaparin) / LEO Pharma
Trial completion: Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=40, Completed, Sponsor: Duke University
Active, not recruiting --> Completed
- | E6201 / Strategia Therap
Trial completion: A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Apr 3, 2012
P2, N=30, Completed, Sponsor: Eisai Limited
Active, not recruiting --> Completed Recruiting --> Completed
- |||| pefcalcitol (M 518101) / Maruho
Trial completion: Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients (clinicaltrials.gov) - Mar 31, 2012
P2, N=294, Completed, Sponsor: Maruho Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- Desonate (desonide gel) / LEO Pharma
New P4 trial: Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation (clinicaltrials.gov) - Feb 29, 2012
P4, N=28, Completed, Sponsor: Universidad Autonoma de San Luis PotosÃ
- ||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: LEO 90100 in the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Feb 20, 2012
P2, N=303, Completed, Sponsor: LEO Pharma
- ||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Feb 20, 2012
P2, N=376, Completed, Sponsor: LEO Pharma
- ||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P2 trial: AMG 827 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Jan 23, 2012
P2, N=168, Active, not recruiting, Sponsor: Amgen
- | Enrollment open: Longheva: Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism (clinicaltrials.gov) - Jan 17, 2012
P3, N=1000, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P1 trial: A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 6, 2011
P1, N=48, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
- ||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
New P2a trial: Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis (clinicaltrials.gov) - Nov 29, 2011
P2a, N=111, Completed, Sponsor: AstraZeneca
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Trial completion: An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris (clinicaltrials.gov) - Nov 17, 2011
P1, N=24, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||||||||| Desonate (desonide gel) / LEO Pharma
New P3 trial: Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (clinicaltrials.gov) - Nov 6, 2011
P3, N=251, Completed, Sponsor: Pierre Fabre Medicament
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
New P1 trial: An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris (clinicaltrials.gov) - Oct 25, 2011
P1, N=24, Completed, Sponsor: LEO Pharma
- || Innohep (tinzaparin) / LEO Pharma
New P3 trial: PERIOP-01: Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer (clinicaltrials.gov) - Oct 18, 2011
P3, N=1075, Recruiting, Sponsor: Ottawa Hospital Research Institute
- LEO 29102 / LEO Pharma
New P1 trial: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Oct 4, 2011
P1, N=58, Terminated, Sponsor: LEO Pharma
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial termination: Long-term Safety Study of Brodalumab in Adults With Crohn's Disease (clinicaltrials.gov) - Sep 21, 2011
P2, N=67, Terminated, Sponsor: Amgen
Not yet recruiting --> Completed Enrolling by invitation --> Terminated; The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial termination: Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Sep 21, 2011
P2, N=130, Terminated, Sponsor: Amgen
Enrolling by invitation --> Terminated; The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups. Recruiting --> Terminated; The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment change: Long-term Safety Study of Brodalumab in Adults With Crohn's Disease (clinicaltrials.gov) - Sep 21, 2011
P2, N=67, Terminated, Sponsor: Amgen
Recruiting --> Terminated; The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups N=216 --> 67
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment change: Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Sep 21, 2011
P2, N=130, Terminated, Sponsor: Amgen
N=216 --> 67 N=216 --> 130
- |||| LEO 22811 / LEO Pharma
Trial completion: A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Sep 11, 2011
P2, N=63, Completed, Sponsor: LEO Pharma
N=216 --> 130 Recruiting --> Completed
- | Innohep (tinzaparin) / LEO Pharma
Enrollment change: Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing (clinicaltrials.gov) - Sep 7, 2011
P4, N=13, Completed, Sponsor: University of Calgary
Recruiting --> Completed N=80 --> 13
- | Innohep (tinzaparin) / LEO Pharma
Trial completion: Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing (clinicaltrials.gov) - Aug 25, 2011
P4, N=13, Completed, Sponsor: University of Calgary
N=80 --> 13 Active, not recruiting --> Completed
- ||| LEO 29102 / LEO Pharma
New P1 trial: Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) - Aug 24, 2011
P1, N=102, Completed, Sponsor: LEO Pharma
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
New P3 trial: LEO 90105 Ointment in Japanese Subjects With Psoriasis (clinicaltrials.gov) - Aug 22, 2011
P3, N=677, Completed, Sponsor: LEO Pharma
- Innohep (tinzaparin) / LEO Pharma
Enrollment open: Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight? (clinicaltrials.gov) - Aug 7, 2011
P4, N=204, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Active, not recruiting --> Recruiting